Health Economics›Malignant pleural mesothelioma›Advanced or metastatic disease first-line therapy

Advanced or metastatic disease first-line therapy

Malignant pleural mesothelioma · 14 regimens

Cost estimates only — modelled on a typical patient (BSA 1.7 m², 70 kg, CrCl 90 mL/min) using the cheapest available formulary presentation. Excludes vial wastage, facility fees, supportive care, and infusion consumables. Not for billing, formulary decisions, or clinical use.

Filters

Y-axis

Cost vs Efficacy · 2 points

Fully pricedPartial pricing

Regimen	Biomarker	Cost/cycle ↓	Cycle	PFS ↕	OS ↕	Est. cycles	Course cost ↕	Evidence
Carboplatin, Pemetrexed, Pembrolizumab Variant #01	—	R 96 550	21d	—	17.3 mo	36	R 3 351 004 PFS proxy	1
Cisplatin, Pemetrexed, Pembrolizumab Variant #01	—	R 95 653	21d	—	17.3 mo	4	R 382 614 PFS proxy	1
Ipilimumab and Nivolumab Variant #01 Partial	—	R 78 615	42d	—	18.1 mo	4	R 314 461 PFS proxy	1
Carboplatin, Pemetrexed, Bevacizumab Variant #01	—	R 44 549	21d	—	18.1 mo	5	R 221 407 PFS proxy	1
Cisplatin, Pemetrexed, Bevacizumab Variant #03	—	R 43 652	21d	—	18.8 mo	6	R 261 915 PFS proxy	1
Carboplatin and Pemetrexed Variant #01	—	R 14 563	21d	—	15.1 mo	6	R 87 376 PFS proxy	2
Cisplatin and Pemetrexed Variant #01	—	R 13 666	21d	7.0 mo	16.1 mo	7	R 94 340 PFS proxy	5
Cisplatin, Pemetrexed, TTFields Variant #01	—	R 13 666	21d	—	—	~6	~R 81 997 indirect	—
Pemetrexed monotherapy Variant #01	—	R 13 225	21d	—	~9.7 mo	~6	~R 79 350 PFS proxy · indirect	—
Cisplatin and Gemcitabine (GC) Variant #01	—	R 3 933	21d	~6.9 mo	~11.9 mo	~6	~R 23 595 PFS proxy · indirect	59
Cisplatin monotherapy Variant #01	—	R 588	21d	—	9.1 mo	6	R 3 530 PFS proxy	2
Vinorelbine monotherapy Variant #01	—	R 458	21d	—	9.5 mo	12	R 5 490 PFS proxy	1
Cisplatin and Raltitrexed Variant #01 Partial	—	R 441	21d	—	11.4 mo	2	R 882 PFS proxy	1
Best supportive care Partial	—	—	—	—	~12.8 mo	—	—	2

14 of 14 regimens shown